Literature DB >> 33123789

Predictive factors of severe abdominal pain during and after transarterial chemoembolization for hepatocellular carcinoma.

Atanas Pachev1, Lucas Raynaud1, Luisa Paulatto1, Marco Dioguardi Burgio1,2, Vincent Roche1,3, Carmela Garcia Alba1, Annie Sibert1, Matthieu Lagadec1, Juliette Kavafyan-Lasserre4, Catherine Paugam-Burtz3,4, Valérie Vilgrain1,2,3, Maxime Ronot5,6,7.   

Abstract

OBJECTIVES: To prospectively assess the frequency of severe abdominal pain during and after transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) using the visual analog scale (VAS), and to identify predictive factors.
METHODS: Ninety-eight TACE performed in 80 patients (mean 65 ± 12 years old, 60 men) were consecutively and prospectively included. Abdominal pain was considered severe if the VAS ≥ 30/100 after treatment administration, or if opioid analgesic (grades 2-3) intake was required during hospitalization. Patient and tumor characteristics as well as technical factors associated with severe pain were identified by binary logistic regression.
RESULTS: The criterion for severe pain was met in 41/98 (42%) of procedures (peri-procedural pain 30/98 [31%] and opioid consumption during hospitalization 24/98 [25%]). Multivariate analysis identified age (odds ratio [OR] = 0.943 (95% confidence interval 0.895-0.994), p = 0.029), cirrhosis (OR = 0.284 (0.083-0.971), p = 0.045), and alcoholic liver disease (OR = 0.081 (0.010-0.659), p = 0.019) as negative predictive factors of severe abdominal pain. Severe abdominal pain occurred in or after 1/13 (8%), 8/34 (24%), 22/41 (54%), and 10/10 (100%) TACE sessions when none, one, two, and three of the protective factors were absent, respectively (p < 0.001). The area under the ROC curve of the combination of factors for the prediction of severe abdominal pain was 0.779 (CI 0.687-0.871).
CONCLUSION: Severe abdominal pain was frequent during and after TACE revealing a clinically relevant and underestimated problem. A predictive model based on three readily available clinical variables suggests that young patients without alcoholic liver disease or cirrhosis could benefit from reinforced analgesia. KEY POINTS: • Severe abdominal pain occurs in 43% of TACE for HCC. • Younger age, absence of cirrhosis, and absence of alcoholic liver disease were identified as independent predictive factors of severe abdominal pain. • A simple combination of the three abovementioned features helped predict the occurrence of severe abdominal pain.

Entities:  

Keywords:  Analgesics, opioid; Chemoembolization, therapeutic; Liver cirrhosis; Pain, measurement; Pain, procedural

Year:  2020        PMID: 33123789     DOI: 10.1007/s00330-020-07404-5

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  2 in total

1.  Post embolization syndrome in doxorubicin eluting chemoembolization with DC bead.

Authors:  Maria Pomoni; Katerina Malagari; Hippokratis Moschouris; Themistoklis N Spyridopoulos; Spyros Dourakis; John Kornezos; Alexios Kelekis; Loukas Thanos; Achilleas Chatziioanou; Ioannis Hatjimarkou; Athanasios Marinis; John Koskinas; Dimitrios Kelekis
Journal:  Hepatogastroenterology       Date:  2012-05

Review 2.  Hepatic nervous system and neurobiology of the liver.

Authors:  Kendal Jay Jensen; Gianfranco Alpini; Shannon Glaser
Journal:  Compr Physiol       Date:  2013-04       Impact factor: 9.090

  2 in total
  2 in total

1.  Construction and Validation of Prediction Model of Severe Abdominal Pain Post-Transarterial Chemoembolization in Patients with HBV-Associated Primary Liver Cancer.

Authors:  Yaobo Yang; Sipan Chen; Zhaoyong Yan; Yang Jiao; Xiang Yan; Yulong Li
Journal:  Comput Math Methods Med       Date:  2022-07-30       Impact factor: 2.809

2.  Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for unresectable hepatocellular carcinoma: A systematic review with meta-analysis.

Authors:  Tengfei Si; Zhenlin Huang; Shirin Elizabeth Khorsandi; Yun Ma; Nigel Heaton
Journal:  Front Bioeng Biotechnol       Date:  2022-09-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.